Clinical Trial Update: A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint [NA]

View source ↗

Summary

A clinical trial is evaluating whether blood testing for the P-tau217 biomarker improves early evaluation and management of patients with subjective cognitive i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subjective Cognitive Impairment

Snippet

Sponsor: Eli Lilly and Company | Conditions: Subjective Cognitive Impairment | NA | Status: RECRUITING